Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours
- 1 April 2006
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 32 (2) , 74-89
- https://doi.org/10.1016/j.ctrv.2006.01.003
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult ratsThe Journal of Gene Medicine, 2003
- EGFR and cancer prognosisPublished by Elsevier ,2001
- Primary and secondary glioblastomas: From concept to clinical diagnosisNeuro-Oncology, 1999
- Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are headingNeuro-Oncology, 1999